Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”

被引：0
|
作者：
Edward E. Neuberger
Josh J. Carlson
David L. Veenstra
机构：
[1] Genentech,The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, Department of Pharmacy
[2] Inc.,undefined
[3] University of Washington,undefined
来源：
PharmacoEconomics | 2021年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：477 / 478
页数：1
相关论文
共 50 条
  • [21] Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Wijnen, Ben
    Armstrong, Nigel
    Ramaekers, Bram
    Witlox, Willem
    Westwood, Marie
    Fayter, Debra
    Ryder, Steve
    Buksnys, Titas
    Worthy, Gill
    Misso, Kate
    Grimm, Sabine
    Kleijnen, Jos
    Joore, Manuela
    PHARMACOECONOMICS, 2020, 38 (10) : 1043 - 1053
  • [22] Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome - Clinical results, neuropsychological effects, and cost-effectiveness
    Majoie, HJM
    Berfelo, MW
    Aldenkamp, AP
    Evers, SMAA
    Kessels, AGH
    Renier, WO
    JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2001, 18 (05) : 419 - 428
  • [23] COST-EFFECTIVENESS OF CANNABIDIOL ADD-ON THERAPY VERSUS PLACEBO FOR THE TREATMENT OF SEIZURES IN TUBEROUS SCLEROSIS COMPLEX
    Bowditch, S.
    Burke, C.
    Crossan, C.
    Hemstock, M.
    Tyas, E.
    Lee, D.
    VALUE IN HEALTH, 2022, 25 (12) : S56 - S56
  • [24] One-year cost-effectiveness of callosotomy vs vagus nerve stimulation for drug-resistant seizures in Lennox-Gastaut Syndrome: A decision analytic model
    Abel, Taylor J.
    Remick, Madison
    Welch, William C.
    Smith, Kenneth J.
    EPILEPSIA OPEN, 2022, 7 (01) : 124 - 130
  • [25] Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom
    Verdian, Lara
    Yi, Yunni
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2010, 19 (01): : 1 - 11
  • [26] Cost-Effectiveness of Specialized Treatment Based on Cognitive Behavioral Therapy Versus Usual Care for Tinnitus
    Maes, Iris H. L.
    Cima, Rilana F. F.
    Anteunis, Lucien J. C.
    Scheijen, Dyon J. W. M.
    Baguley, David M.
    El Refaie, Amr
    Vlaeyen, Johannes W.
    Joore, Manuela A.
    OTOLOGY & NEUROTOLOGY, 2014, 35 (05) : 787 - 795
  • [27] COST-EFFECTIVENESS OF SPECIALIZED TREATMENT BASED ON COGNITIVE BEHAVIOURAL THERAPY VERSUS USUAL CARE FOR TINNITUS
    Maes, I. H.
    Cima, R. F.
    Anteunis, L. J.
    Baguley, D. M.
    El Refaie, A.
    Scheijen, D. J.
    Vlaeyen, J. J.
    Joore, M. A.
    VALUE IN HEALTH, 2012, 15 (07) : A570 - A570
  • [28] Cost effectiveness analyses of rufinamide vs topiramate and lamotrigine as adjunctive therapies in the treatment of Lennox-Gastaut syndrome (LGS) in the United Kingdom
    Benedict, A.
    Dale, P. L.
    MacLaine, G.
    Verdian, L.
    VALUE IN HEALTH, 2007, 10 (06) : A382 - A383
  • [29] Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany☆
    Strzelczyk, Adam
    Schubert-Bast, Susanne
    von Podewils, Felix
    Knake, Susanne
    Mayer, Thomas
    Klotz, Kerstin Alexandra
    Buhleier, Elisa
    Herold, Luise
    Immisch, Ilka
    Kurlemann, Gerhard
    Rosenow, Felix
    EPILEPSY & BEHAVIOR, 2025, 166
  • [30] Cost-effectiveness of multisystemic therapy versus usual treatment for young people with antisocial problems
    Vermeulen, Karin M.
    Jansen, Danielle E. M. C.
    Knorth, Erik J.
    Buskens, Erik
    Reijneveld, Sijmen A.
    CRIMINAL BEHAVIOUR AND MENTAL HEALTH, 2017, 27 (01) : 89 - 102
12345